Ya Hui Hung
YOU?
Author Swipe
View article: Delivery of mRNA encoding an anti‐tau monoclonal antibody and engineered scFv intrabody results in functional antibody expression in neurons
Delivery of mRNA encoding an anti‐tau monoclonal antibody and engineered scFv intrabody results in functional antibody expression in neurons Open
Background Monoclonal antibodies have emerged as a leading therapeutic agent for the treatment of disease, including Alzheimer’s disease. Such antibodies, however, are expensive and timely to produce and require frequent dosing regimens to…
View article: Small extracellular vesicles contain metals and transfer metal intercellularly
Small extracellular vesicles contain metals and transfer metal intercellularly Open
Cells have developed a highly regulated system for the uptake, transport, utilization, storage, and export of metals, ensuring the maintenance of cellular homeostasis. Small extracellular vesicles (sEVs) function as a mechanism through whi…
View article: Impaired cellular copper regulation in the presence of <scp>ApoE4</scp>
Impaired cellular copper regulation in the presence of <span>ApoE4</span> Open
The strongest genetic risk factor for late‐onset Alzheimer's disease (AD) is allelic variation of the APOE gene, with the following risk structure: ε4 > ε3 > ε2. The biochemical basis for this risk profile is unclear. Here, we reveal a new…
View article: Messenger RNA-encoded antibody approach for targeting extracellular and intracellular tau
Messenger RNA-encoded antibody approach for targeting extracellular and intracellular tau Open
Monoclonal antibodies have emerged as a leading therapeutic agent for the treatment of disease, including Alzheimer’s disease. In the last year, two anti-amyloid monoclonal antibodies, lecanemab and aducanumab, have been approved in the US…
View article: Neuronal targeting of tau using a mRNA‐encoded tau‐specific antibody fragment
Neuronal targeting of tau using a mRNA‐encoded tau‐specific antibody fragment Open
Background A promising target for the treatment of Alzheimer’s disease and related tauopathies is intraneuronal tau. We have generated conventional tau‐specific monoclonal antibodies, as well as engineered antibody fragments, and demonstra…
View article: Delivery of mRNA encoding an anti-tau monoclonal antibody and engineered scFv intrabody results in functional antibody expression in SH-SY5Y cells
Delivery of mRNA encoding an anti-tau monoclonal antibody and engineered scFv intrabody results in functional antibody expression in SH-SY5Y cells Open
Monoclonal antibodies have emerged as a leading therapeutic agent for the treatment of disease, including Alzheimer’s disease. In the last year, two anti-amyloid monoclonal antibodies, lecanemab and aducanumab, have been approved in the US…
View article: mRNA Treatment Rescues Niemann-Pick Disease Type C1 in Patient Fibroblasts
mRNA Treatment Rescues Niemann-Pick Disease Type C1 in Patient Fibroblasts Open
Messenger RNA (mRNA) holds great potential as a disease-modifying treatment for a wide array of monogenic disorders. Niemann-Pick disease type C1 (NP-C1) is an ultra-rare monogenic disease that arises due to loss-of-function mutations in t…
View article: Severely impaired CTL killing is a feature of the neurological disorder Niemann-Pick disease type C1
Severely impaired CTL killing is a feature of the neurological disorder Niemann-Pick disease type C1 Open
Niemann-Pick disease type C1 (NP-C1) is a rare lysosomal storage disorder resulting from mutations in an endolysosomal cholesterol transporter, NPC1. Despite typically presenting with pronounced neurological manifestations, NP-C1 also rese…
View article: Neurological Dysfunction in Early Maturity of a Model for Niemann–Pick C1 Carrier Status
Neurological Dysfunction in Early Maturity of a Model for Niemann–Pick C1 Carrier Status Open